8-K: CG Oncology Announces Positive Interim Phase 3 Data for Bladder Cancer Treatment

CG Oncology's Phase 3 trial of cretostimogene shows a 75.2% complete response rate in patients with high-risk bladder cancer unresponsive to BCG treatment.

Summary

• CG Oncology announced interim results from its Phase 3 BOND-003 study for cretostimogene, a treatment for high-risk Non-Muscle-Invasive Bladder Cancer (NMIBC) that is unresponsive to Bacillus Calmette-Guerin (BCG).
• The study showed a 75.2% complete response (CR) rate at any time, with 79 out of 105 patients achieving CR as of April 1, 2024.
• 29 patients have maintained a CR for 12 months or more, with 22 additional patients still being evaluated for ongoing responses.
• The median duration of response (DOR) has not been reached as of the data cutoff date.
• 53.8% of patients who received repeat induction therapy converted to a CR.
• 92.4% of patients experienced cystectomy-free survival, and no patients with a CR required radical cystectomy or showed nodal or metastatic progression.
• The trial is a single-arm study with 112 patients enrolled globally in North America and the Asia-Pacific region.
• The primary endpoint is CR at any time, and the secondary endpoint is DOR.
• The study population includes patients with prior intravesical chemotherapy and systemic immunotherapy.
• Topline data from the BOND-003 trial is expected by the end of 2024.
• Cretostimogene was generally well-tolerated, with no Grade 3 or higher treatment-related adverse events (TRAEs) or deaths reported as of January 31, 2024.
• Two patients (1.8%) experienced serious Grade 2 TRAEs, and no treatment-related discontinuations were observed.
• 94.5% of patients completed all expected treatments, with a 100% successful instillation rate.

Sentiment

Score: 8

Explanation: The document presents very positive interim results from a Phase 3 trial, with a high complete response rate and good tolerability. While there are risks associated with clinical trials, the overall tone is optimistic and suggests a promising treatment option.

Positives

• The 75.2% complete response rate is a very promising result for patients with high-risk NMIBC.
• The durability of the response, with 29 patients maintaining CR for 12 months or more, is encouraging.
• The high cystectomy-free survival rate of 92.4% suggests a significant benefit for patients.
• The treatment was generally well-tolerated, with no Grade 3 or higher treatment-related adverse events or deaths reported.
• The high completion rate of treatments and successful instillation rate indicate good patient compliance and treatment administration.

Negatives

• Two patients (1.8%) experienced serious Grade 2 treatment-related adverse events, specifically cystitis noninfective and clot retention.
• Treatment-related adverse events occurred in 62.5% of patients, with the most common being bladder spasm, pollakiuria, dysuria, micturition urgency, and hematuria.

Risks

• Interim results may not be indicative of final results, and clinical outcomes may change as patient enrollment continues and more data becomes available.
• There are potential delays in the commencement, enrollment, data readout, and completion of clinical trials.
• The company is dependent on third parties for manufacturing, shipping, and clinical testing.
• Results from earlier clinical trials and preclinical studies may not predict future results.
• Unexpected adverse side effects or inadequate efficacy of cretostimogene could limit its development, regulatory approval, and commercialization.

Future Outlook

The company expects to report topline data from the BOND-003 trial by the end of 2024.

Management Comments

• Dr. Mark D. Tyson, urologic oncologist at Mayo Clinic, presented the data at the 2024 American Urological Association Annual Meeting.

Industry Context

This announcement is significant in the field of urology and oncology, as it presents a potential new treatment option for patients with high-risk NMIBC who have not responded to BCG therapy, a common first-line treatment. The high complete response rate could position cretostimogene as a valuable alternative.

Comparison to Industry Standards

• Current standard treatments for BCG-unresponsive NMIBC often involve radical cystectomy, which is a major surgery with significant morbidity. The 92.4% cystectomy-free survival rate in this study is a significant improvement over the outcomes of patients who undergo cystectomy.
• Other therapies in development for NMIBC include checkpoint inhibitors and other intravesical agents. The 75.2% complete response rate for cretostimogene compares favorably to the response rates seen with some of these other therapies in similar patient populations.
• For example, pembrolizumab, a checkpoint inhibitor, has shown complete response rates in the range of 40-50% in BCG-unresponsive NMIBC. The results for cretostimogene appear to be better than this.
• Companies like Merck and Bristol Myers Squibb are also developing treatments for NMIBC, but the specific results of their trials vary. The data from CG Oncology is very competitive in this space.

Stakeholder Impact

• Shareholders may react positively to the strong interim results, potentially increasing the company's stock value.
• Patients with high-risk NMIBC may have a new and effective treatment option.
• Healthcare providers may be interested in adopting cretostimogene as a treatment option if approved.
• Employees of CG Oncology may be motivated by the positive results and the potential for the company's success.

Next Steps

• The company will continue to monitor patients in the BOND-003 trial.
• The company expects to report topline data from the BOND-003 trial by the end of 2024.

Key Dates

Keywords

cretostimogene, bladder cancer, NMIBC, BCG-unresponsive, clinical trial, complete response, BOND-003, oncology, urology, cancer treatment